A novel mechanism for immune regulation after human lung transplantation
Identifieur interne : 000941 ( Pmc/Corpus ); précédent : 000940; suivant : 000942A novel mechanism for immune regulation after human lung transplantation
Auteurs : Thalachallour Mohanakumar ; Monal Sharma ; Sandhya Bansal ; Ranjithkumar Ravichandran ; Michael A. Smith ; Ross M. BremnerSource :
- The Journal of Thoracic and Cardiovascular Surgery [ 0022-5223 ] ; 2019.
Abstract
Lung transplantation is therapeutic for end-stage lung disease, but survival is limited due to bronchiolitis obliterans syndrome and restrictive chronic lung allograft dysfunction. We sought a common denominator in lung transplant recipients, analyzing risk factors that trigger immune responses that lead to bronchiolitis obliterans syndrome.
We collected blood from patients who underwent lung transplant at our institution. Exosomes were isolated from the sera of recipients with risk factors for chronic rejection and from stable recipients. Exosomes were analyzed with western blot, using antibodies to lung self-antigens K alpha 1 tubulin and collagen-V, costimulatory molecules (costimulatory molecule 80, costimulatory molecule 86), transcription factors (nuclear factor kappa-light-chain-enhancer of activated B cells, hypoxia-inducible factor 1α, Class II Major Histocompatibility Complex Transactivator), and 20S proteasome.
Of the 90 patients included, we identified 5 with grade 3 primary graft dysfunction, 5 without, 15 with respiratory viral infection, 10 with acute rejection, 10 with donor-specific antibodies (DSA), 5 without DSA, and 10 who were stable for exosome isolation. Recipients with grade 3 primary graft dysfunction, respiratory viral infection, acute rejection, and DSA had exosomes containing self-antigens; exosomes from stable recipients did not. Exosomes from recipients with grade 3 primary graft dysfunction, acute rejection, and DSA also demonstrated costimulatory molecule 80, costimulatory molecule 86, major histocompatibility complex class II, transcription factor, and 20S proteasome.
Transplanted lungs with grade 3 primary graft dysfunction, symptomatic respiratory viral infection, acute rejection, and immune responses induce exosomes that contain self-antigens, costimulatory molecules, major histocompatibility complex class II, transcription factors, and 20S proteasome. Release of circulating exosomes post-transplant from the aforementioned stress-inducing insults augment immunity and may play an important role in the pathogenesis of bronchiolitis obliterans syndrome.
Url:
DOI: 10.1016/j.jtcvs.2018.12.105
PubMed: 31288367
PubMed Central: 6625531
Links to Exploration step
PMC:6625531Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A novel mechanism for immune regulation after human lung transplantation</title><author><name sortKey="Mohanakumar, Thalachallour" sort="Mohanakumar, Thalachallour" uniqKey="Mohanakumar T" first="Thalachallour" last="Mohanakumar">Thalachallour Mohanakumar</name></author><author><name sortKey="Sharma, Monal" sort="Sharma, Monal" uniqKey="Sharma M" first="Monal" last="Sharma">Monal Sharma</name></author><author><name sortKey="Bansal, Sandhya" sort="Bansal, Sandhya" uniqKey="Bansal S" first="Sandhya" last="Bansal">Sandhya Bansal</name></author><author><name sortKey="Ravichandran, Ranjithkumar" sort="Ravichandran, Ranjithkumar" uniqKey="Ravichandran R" first="Ranjithkumar" last="Ravichandran">Ranjithkumar Ravichandran</name></author><author><name sortKey="Smith, Michael A" sort="Smith, Michael A" uniqKey="Smith M" first="Michael A." last="Smith">Michael A. Smith</name></author><author><name sortKey="Bremner, Ross M" sort="Bremner, Ross M" uniqKey="Bremner R" first="Ross M." last="Bremner">Ross M. Bremner</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31288367</idno><idno type="pmc">6625531</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625531</idno><idno type="RBID">PMC:6625531</idno><idno type="doi">10.1016/j.jtcvs.2018.12.105</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000941</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000941</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A novel mechanism for immune regulation after human lung transplantation</title><author><name sortKey="Mohanakumar, Thalachallour" sort="Mohanakumar, Thalachallour" uniqKey="Mohanakumar T" first="Thalachallour" last="Mohanakumar">Thalachallour Mohanakumar</name></author><author><name sortKey="Sharma, Monal" sort="Sharma, Monal" uniqKey="Sharma M" first="Monal" last="Sharma">Monal Sharma</name></author><author><name sortKey="Bansal, Sandhya" sort="Bansal, Sandhya" uniqKey="Bansal S" first="Sandhya" last="Bansal">Sandhya Bansal</name></author><author><name sortKey="Ravichandran, Ranjithkumar" sort="Ravichandran, Ranjithkumar" uniqKey="Ravichandran R" first="Ranjithkumar" last="Ravichandran">Ranjithkumar Ravichandran</name></author><author><name sortKey="Smith, Michael A" sort="Smith, Michael A" uniqKey="Smith M" first="Michael A." last="Smith">Michael A. Smith</name></author><author><name sortKey="Bremner, Ross M" sort="Bremner, Ross M" uniqKey="Bremner R" first="Ross M." last="Bremner">Ross M. Bremner</name></author></analytic><series><title level="j">The Journal of Thoracic and Cardiovascular Surgery</title><idno type="ISSN">0022-5223</idno><idno type="eISSN">1097-685X</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objective</title><p>Lung transplantation is therapeutic for end-stage lung disease, but survival is limited due to bronchiolitis obliterans syndrome and restrictive chronic lung allograft dysfunction. We sought a common denominator in lung transplant recipients, analyzing risk factors that trigger immune responses that lead to bronchiolitis obliterans syndrome.</p></sec><sec><title>Methods</title><p>We collected blood from patients who underwent lung transplant at our institution. Exosomes were isolated from the sera of recipients with risk factors for chronic rejection and from stable recipients. Exosomes were analyzed with western blot, using antibodies to lung self-antigens K alpha 1 tubulin and collagen-V, costimulatory molecules (costimulatory molecule 80, costimulatory molecule 86), transcription factors (nuclear factor kappa-light-chain-enhancer of activated B cells, hypoxia-inducible factor 1α, Class II Major Histocompatibility Complex Transactivator), and 20S proteasome.</p></sec><sec><title>Results</title><p>Of the 90 patients included, we identified 5 with grade 3 primary graft dysfunction, 5 without, 15 with respiratory viral infection, 10 with acute rejection, 10 with donor-specific antibodies (DSA), 5 without DSA, and 10 who were stable for exosome isolation. Recipients with grade 3 primary graft dysfunction, respiratory viral infection, acute rejection, and DSA had exosomes containing self-antigens; exosomes from stable recipients did not. Exosomes from recipients with grade 3 primary graft dysfunction, acute rejection, and DSA also demonstrated costimulatory molecule 80, costimulatory molecule 86, major histocompatibility complex class II, transcription factor, and 20S proteasome.</p></sec><sec><title>Conclusions</title><p>Transplanted lungs with grade 3 primary graft dysfunction, symptomatic respiratory viral infection, acute rejection, and immune responses induce exosomes that contain self-antigens, costimulatory molecules, major histocompatibility complex class II, transcription factors, and 20S proteasome. Release of circulating exosomes post-transplant from the aforementioned stress-inducing insults augment immunity and may play an important role in the pathogenesis of bronchiolitis obliterans syndrome.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Arcasoy, S M" uniqKey="Arcasoy S">S.M. Arcasoy</name></author><author><name sortKey="Kotloff, R M" uniqKey="Kotloff R">R.M. Kotloff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trulock, E P" uniqKey="Trulock E">E.P. Trulock</name></author><author><name sortKey="Edwards, L B" uniqKey="Edwards L">L.B. Edwards</name></author><author><name sortKey="Taylor, D O" uniqKey="Taylor D">D.O. Taylor</name></author><author><name sortKey="Boucek, M M" uniqKey="Boucek M">M.M. Boucek</name></author><author><name sortKey="Keck, B M" uniqKey="Keck B">B.M. Keck</name></author><author><name sortKey="Hertz, M I" uniqKey="Hertz M">M.I. Hertz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Estenne, M" uniqKey="Estenne M">M. Estenne</name></author><author><name sortKey="Hertz, M I" uniqKey="Hertz M">M.I. Hertz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jaramillo, A" uniqKey="Jaramillo A">A. Jaramillo</name></author><author><name sortKey="Smith, M A" uniqKey="Smith M">M.A. Smith</name></author><author><name sortKey="Phelan, D" uniqKey="Phelan D">D. Phelan</name></author><author><name sortKey="Sundaresan, S" uniqKey="Sundaresan S">S. Sundaresan</name></author><author><name sortKey="Trulock, E P" uniqKey="Trulock E">E.P. Trulock</name></author><author><name sortKey="Lynch, J P" uniqKey="Lynch J">J.P. Lynch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hachem, R R" uniqKey="Hachem R">R.R. Hachem</name></author><author><name sortKey="Yusen, R D" uniqKey="Yusen R">R.D. Yusen</name></author><author><name sortKey="Meyers, B F" uniqKey="Meyers B">B.F. Meyers</name></author><author><name sortKey="Aloush, A A" uniqKey="Aloush A">A.A. Aloush</name></author><author><name sortKey="Mohanakumar, T" uniqKey="Mohanakumar T">T. Mohanakumar</name></author><author><name sortKey="Patterson, G A" uniqKey="Patterson G">G.A. Patterson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bharat, A" uniqKey="Bharat A">A. Bharat</name></author><author><name sortKey="Saini, D" uniqKey="Saini D">D. Saini</name></author><author><name sortKey="Steward, N" uniqKey="Steward N">N. Steward</name></author><author><name sortKey="Hachem, R" uniqKey="Hachem R">R. Hachem</name></author><author><name sortKey="Trulock, E P" uniqKey="Trulock E">E.P. Trulock</name></author><author><name sortKey="Patterson, G A" uniqKey="Patterson G">G.A. Patterson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bharat, A" uniqKey="Bharat A">A. Bharat</name></author><author><name sortKey="Kuo, E" uniqKey="Kuo E">E. Kuo</name></author><author><name sortKey="Saini, D" uniqKey="Saini D">D. Saini</name></author><author><name sortKey="Steward, N" uniqKey="Steward N">N. Steward</name></author><author><name sortKey="Hachem, R" uniqKey="Hachem R">R. Hachem</name></author><author><name sortKey="Trulock, E P" uniqKey="Trulock E">E.P. Trulock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Almaghrabi, R S" uniqKey="Almaghrabi R">R.S. Almaghrabi</name></author><author><name sortKey="Omrani, A S" uniqKey="Omrani A">A.S. Omrani</name></author><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fisher, C E" uniqKey="Fisher C">C.E. Fisher</name></author><author><name sortKey="Mohanakumar, T" uniqKey="Mohanakumar T">T. Mohanakumar</name></author><author><name sortKey="Limaye, A P" uniqKey="Limaye A">A.P. Limaye</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aguilar, P R" uniqKey="Aguilar P">P.R. Aguilar</name></author><author><name sortKey="Carpenter, D" uniqKey="Carpenter D">D. Carpenter</name></author><author><name sortKey="Ritter, J" uniqKey="Ritter J">J. Ritter</name></author><author><name sortKey="Yusen, R D" uniqKey="Yusen R">R.D. Yusen</name></author><author><name sortKey="Witt, C A" uniqKey="Witt C">C.A. Witt</name></author><author><name sortKey="Byers, D E" uniqKey="Byers D">D.E. Byers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, Z" uniqKey="Xu Z">Z. Xu</name></author><author><name sortKey="Yang, W" uniqKey="Yang W">W. Yang</name></author><author><name sortKey="Steward, N" uniqKey="Steward N">N. Steward</name></author><author><name sortKey="Sweet, S C" uniqKey="Sweet S">S.C. Sweet</name></author><author><name sortKey="Danziger Isakov, L" uniqKey="Danziger Isakov L">L. Danziger-Isakov</name></author><author><name sortKey="Heeger, P S" uniqKey="Heeger P">P.S. Heeger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simpson, R J" uniqKey="Simpson R">R.J. Simpson</name></author><author><name sortKey="Jensen, S S" uniqKey="Jensen S">S.S. Jensen</name></author><author><name sortKey="Lim, J W E" uniqKey="Lim J">J.W.E. Lim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raimondo, F" uniqKey="Raimondo F">F. Raimondo</name></author><author><name sortKey="Morosi, L" uniqKey="Morosi L">L. Morosi</name></author><author><name sortKey="Chinello, C" uniqKey="Chinello C">C. Chinello</name></author><author><name sortKey="Magni, F" uniqKey="Magni F">F. Magni</name></author><author><name sortKey="Pitto, M" uniqKey="Pitto M">M. Pitto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Melo, S A" uniqKey="Melo S">S.A. Melo</name></author><author><name sortKey="Sugimoto, H" uniqKey="Sugimoto H">H. Sugimoto</name></author><author><name sortKey="O Connell, J T" uniqKey="O Connell J">J.T. O'Connell</name></author><author><name sortKey="Kato, N" uniqKey="Kato N">N. Kato</name></author><author><name sortKey="Villanueva, A" uniqKey="Villanueva A">A. Villanueva</name></author><author><name sortKey="Vidal, A" uniqKey="Vidal A">A. Vidal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gregson, A L" uniqKey="Gregson A">A.L. Gregson</name></author><author><name sortKey="Hoji, A" uniqKey="Hoji A">A. Hoji</name></author><author><name sortKey="Injean, P" uniqKey="Injean P">P. Injean</name></author><author><name sortKey="Poynter, S T" uniqKey="Poynter S">S.T. Poynter</name></author><author><name sortKey="Briones, C" uniqKey="Briones C">C. Briones</name></author><author><name sortKey="Palchevskiy, V" uniqKey="Palchevskiy V">V. Palchevskiy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gunasekaran, M" uniqKey="Gunasekaran M">M. Gunasekaran</name></author><author><name sortKey="Xu, Z" uniqKey="Xu Z">Z. Xu</name></author><author><name sortKey="Nayak, D K" uniqKey="Nayak D">D.K. Nayak</name></author><author><name sortKey="Sharma, M" uniqKey="Sharma M">M. Sharma</name></author><author><name sortKey="Hachem, R" uniqKey="Hachem R">R. Hachem</name></author><author><name sortKey="Walia, R" uniqKey="Walia R">R. Walia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jaramillo, A" uniqKey="Jaramillo A">A. Jaramillo</name></author><author><name sortKey="Smith, C R" uniqKey="Smith C">C.R. Smith</name></author><author><name sortKey="Maruyama, T" uniqKey="Maruyama T">T. Maruyama</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L. Zhang</name></author><author><name sortKey="Patterson, G A" uniqKey="Patterson G">G.A. Patterson</name></author><author><name sortKey="Mohanakumar, T" uniqKey="Mohanakumar T">T. Mohanakumar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Logozzi, M" uniqKey="Logozzi M">M. Logozzi</name></author><author><name sortKey="Angelini, D F" uniqKey="Angelini D">D.F. Angelini</name></author><author><name sortKey="Iessi, E" uniqKey="Iessi E">E. Iessi</name></author><author><name sortKey="Mizzoni, D" uniqKey="Mizzoni D">D. Mizzoni</name></author><author><name sortKey="Diraimo, R" uniqKey="Diraimo R">R. DiRaimo</name></author><author><name sortKey="Federic, C" uniqKey="Federic C">C. Federic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weigt, S S" uniqKey="Weigt S">S.S. Weigt</name></author><author><name sortKey="Wang, X" uniqKey="Wang X">X. Wang</name></author><author><name sortKey="Palchevsky, V" uniqKey="Palchevsky V">V. Palchevsky</name></author><author><name sortKey="Gregson, A L" uniqKey="Gregson A">A.L. Gregson</name></author><author><name sortKey="Patel, N" uniqKey="Patel N">N. Patel</name></author><author><name sortKey="Derhovanessian, A" uniqKey="Derhovanessian A">A. DerHovanessian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morelli, A E" uniqKey="Morelli A">A.E. Morelli</name></author><author><name sortKey="Bracamonte Baran, W" uniqKey="Bracamonte Baran W">W. Bracamonte-Baran</name></author><author><name sortKey="Burlingham, W J" uniqKey="Burlingham W">W.J. Burlingham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Q" uniqKey="Liu Q">Q. Liu</name></author><author><name sortKey="Rojas Canales, D M" uniqKey="Rojas Canales D">D.M. Rojas-Canales</name></author><author><name sortKey="Divito, S J" uniqKey="Divito S">S.J. Divito</name></author><author><name sortKey="Shufesky, W J" uniqKey="Shufesky W">W.J. Shufesky</name></author><author><name sortKey="Stolz, D B" uniqKey="Stolz D">D.B. Stolz</name></author><author><name sortKey="Erdos, G" uniqKey="Erdos G">G. Erdos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gunasekaran, M" uniqKey="Gunasekaran M">M. Gunasekaran</name></author><author><name sortKey="Sharma, M" uniqKey="Sharma M">M. Sharma</name></author><author><name sortKey="Hachem, R" uniqKey="Hachem R">R. Hachem</name></author><author><name sortKey="Bremner, R" uniqKey="Bremner R">R. Bremner</name></author><author><name sortKey="Smith, M A" uniqKey="Smith M">M.A. Smith</name></author><author><name sortKey="Mohanakumar, T" uniqKey="Mohanakumar T">T. Mohanakumar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sharma, M" uniqKey="Sharma M">M. Sharma</name></author><author><name sortKey="Liu, W" uniqKey="Liu W">W. Liu</name></author><author><name sortKey="Perincheri, S" uniqKey="Perincheri S">S. Perincheri</name></author><author><name sortKey="Gunasekaran, M" uniqKey="Gunasekaran M">M. Gunasekaran</name></author><author><name sortKey="Mohanakumar, T" uniqKey="Mohanakumar T">T. Mohanakumar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dieude, M" uniqKey="Dieude M">M. Dieude</name></author><author><name sortKey="Bell, C" uniqKey="Bell C">C. Bell</name></author><author><name sortKey="Turgeon, J" uniqKey="Turgeon J">J. Turgeon</name></author><author><name sortKey="Beillevaire, D" uniqKey="Beillevaire D">D. Beillevaire</name></author><author><name sortKey="Pomerleau, L" uniqKey="Pomerleau L">L. Pomerleau</name></author><author><name sortKey="Yang, B" uniqKey="Yang B">B. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tower, C M" uniqKey="Tower C">C.M. Tower</name></author><author><name sortKey="Reyes, M" uniqKey="Reyes M">M. Reyes</name></author><author><name sortKey="Nelson, K" uniqKey="Nelson K">K. Nelson</name></author><author><name sortKey="Leca, N" uniqKey="Leca N">N. Leca</name></author><author><name sortKey="Kieran, N" uniqKey="Kieran N">N. Kieran</name></author><author><name sortKey="Muczynski, K" uniqKey="Muczynski K">K. Muczynski</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Thorac Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">J. Thorac. Cardiovasc. Surg</journal-id><journal-title-group><journal-title>The Journal of Thoracic and Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0022-5223</issn><issn pub-type="epub">1097-685X</issn><publisher><publisher-name>Mosby</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31288367</article-id><article-id pub-id-type="pmc">6625531</article-id><article-id pub-id-type="publisher-id">S0022-5223(19)30343-5</article-id><article-id pub-id-type="doi">10.1016/j.jtcvs.2018.12.105</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A novel mechanism for immune regulation after human lung transplantation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Mohanakumar</surname><given-names>Thalachallour</given-names></name><degrees>PhD</degrees><email>Tm.kumar@dignityhealth.org</email><xref rid="cor1" ref-type="corresp">∗</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Sharma</surname><given-names>Monal</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author" id="au3"><name><surname>Bansal</surname><given-names>Sandhya</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author" id="au4"><name><surname>Ravichandran</surname><given-names>Ranjithkumar</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author" id="au5"><name><surname>Smith</surname><given-names>Michael A.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" id="au6"><name><surname>Bremner</surname><given-names>Ross M.</given-names></name><degrees>MD, PhD</degrees></contrib></contrib-group><aff id="aff1">Norton Thoracic Institute, St Joseph's Hospital and Medical Center, Phoenix, Ariz</aff><author-notes><corresp id="cor1"><label>∗</label>Address for reprints: Thalachallour Mohanakumar, PhD, Norton Thoracic Institute, St Joseph's Hospital and Medical Center, 124 W Thomas Rd, Suite 105, Phoenix, AZ 85013. <email>Tm.kumar@dignityhealth.org</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>12</day><month>2</month><year>2019</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>5</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>12</day><month>2</month><year>2019</year></pub-date><volume>157</volume><issue>5</issue><fpage>2096</fpage><lpage>2106</lpage><history><date date-type="received"><day>22</day><month>6</month><year>2018</year></date><date date-type="rev-recd"><day>13</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>2</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>© 2019 by The American Association for Thoracic Surgery.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The American Association for Thoracic Surgery</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><sec><title>Objective</title><p>Lung transplantation is therapeutic for end-stage lung disease, but survival is limited due to bronchiolitis obliterans syndrome and restrictive chronic lung allograft dysfunction. We sought a common denominator in lung transplant recipients, analyzing risk factors that trigger immune responses that lead to bronchiolitis obliterans syndrome.</p></sec><sec><title>Methods</title><p>We collected blood from patients who underwent lung transplant at our institution. Exosomes were isolated from the sera of recipients with risk factors for chronic rejection and from stable recipients. Exosomes were analyzed with western blot, using antibodies to lung self-antigens K alpha 1 tubulin and collagen-V, costimulatory molecules (costimulatory molecule 80, costimulatory molecule 86), transcription factors (nuclear factor kappa-light-chain-enhancer of activated B cells, hypoxia-inducible factor 1α, Class II Major Histocompatibility Complex Transactivator), and 20S proteasome.</p></sec><sec><title>Results</title><p>Of the 90 patients included, we identified 5 with grade 3 primary graft dysfunction, 5 without, 15 with respiratory viral infection, 10 with acute rejection, 10 with donor-specific antibodies (DSA), 5 without DSA, and 10 who were stable for exosome isolation. Recipients with grade 3 primary graft dysfunction, respiratory viral infection, acute rejection, and DSA had exosomes containing self-antigens; exosomes from stable recipients did not. Exosomes from recipients with grade 3 primary graft dysfunction, acute rejection, and DSA also demonstrated costimulatory molecule 80, costimulatory molecule 86, major histocompatibility complex class II, transcription factor, and 20S proteasome.</p></sec><sec><title>Conclusions</title><p>Transplanted lungs with grade 3 primary graft dysfunction, symptomatic respiratory viral infection, acute rejection, and immune responses induce exosomes that contain self-antigens, costimulatory molecules, major histocompatibility complex class II, transcription factors, and 20S proteasome. Release of circulating exosomes post-transplant from the aforementioned stress-inducing insults augment immunity and may play an important role in the pathogenesis of bronchiolitis obliterans syndrome.</p></sec></abstract><kwd-group id="kwrds0010"><title>Key Words</title><kwd>lung transplant</kwd><kwd>circulatory exosomes</kwd><kwd>rejection</kwd><kwd>primary graft dysfunction</kwd><kwd>novel mechanism</kwd><kwd>acute rejection</kwd><kwd>DSA</kwd></kwd-group><kwd-group id="kwrds0015"><title>Abbreviations and Acronyms</title><kwd>Abs, antibodies</kwd><kwd>AEC, airway epithelial cell line</kwd><kwd>AR, acute rejection</kwd><kwd>BALF, bronchoalveolar lavage fluid</kwd><kwd>BOS, bronchiolitis obliterans syndrome</kwd><kwd>CD80, costimulatory molecule 80</kwd><kwd>CD86, costimulatory molecule 86</kwd><kwd>CIITA, Class II Major Histocompatibility Complex Transactivator</kwd><kwd>CLAD, chronic lung allograft dysfunction</kwd><kwd>Col-V, collagen V</kwd><kwd>CR, chronic rejection</kwd><kwd>DSA, donor-specific antibodies</kwd><kwd>HIF-1α, hypoxia-inducible factor 1α</kwd><kwd>HLA, human leukocyte antigen</kwd><kwd>ICAM, intercellular adhesion molecule</kwd><kwd>Kα1T, K alpha 1 tubulin</kwd><kwd>LTx, lung transplantation</kwd><kwd>LTxRs, lung transplant recipients</kwd><kwd>MHC, major histocompatibility complex</kwd><kwd>miRNA, microRNA</kwd><kwd>NF-κβ, nuclear factor kappa-light-chain-enhancer of activated B cells</kwd><kwd>PBS, phosphate-buffered saline</kwd><kwd>PGD, primary graft dysfunction</kwd><kwd>RVI, respiratory viral infection</kwd><kwd>SAgs, self-antigens</kwd><kwd>VCAM, vascular cell adhesion molecule</kwd></kwd-group></article-meta></front><body><p id="p0010"><fig id="undfig1"><caption><p>Induction of exosomes may be a mechanism for development of chronic allograft rejection.</p></caption><graphic xlink:href="fx1_lrg"></graphic></fig><boxed-text id="dtbox1"><caption><title>Central Message</title></caption><p id="p0015">Risk for bronchiolitis obliterans syndrome after lung transplant by primary graft dysfunction, viral infections, and allo-immune responses may be mediated by exosomes with allo and lung antigens.</p></boxed-text><boxed-text id="dtbox2"><caption><title>Perspective</title></caption><p id="p0020">This provides a mechanism by which primary graft dysfunction, respiratory viral infection, acute rejection, and anti-HLA leads to bronchiolitis obliterans syndrome (BOS) post-lung transplant. All can lead to induction, release of exosomes with donor HLA, and lung antigens resulting in increased immune responses. Monitoring circulating exosomes can be a potential biomarker for patients at risk for BOS.</p></boxed-text><boxed-text id="dtbox3"><p id="p0175a">See Commentary on page 2107.</p></boxed-text></p><p id="p0025">Human lung transplantation (LTx) is a viable treatment option for patients with end-stage lung diseases such as idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and cystic fibrosis.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref> Short-term survival has improved, but acute rejection (AR) and chronic rejection (CR) in the form of chronic lung allograft dysfunction (CLAD) remain obstacles to long-term allograft function. CLAD currently includes both restrictive airway disease and an obstructive form of pathology called bronchiolitis obliterans syndrome (BOS). Roughly 50% of LTx recipients (LTxRs) develop BOS within 5 years of LTx.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Both AR and BOS are considered primarily due to immunologic insults to the transplanted lungs. Some have reported a significant correlation between BOS and de novo development of antibodies (Abs) to mismatched donor human leukocyte antigen (HLA) (donor-specific antibodies [DSA]) and Abs to lung-associated self-antigens (SAgs), K alpha 1 tubulin (Kα1T), and collagen V (Col-V) after LTx.<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> In addition, primary graft dysfunction (PGD),<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> respiratory viral infections (RVIs),<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> and number of AR episodes<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref> are thought to increase the risk for development of BOS.</p><p id="p0030">The mechanisms by which all of the aforementioned risk factors lead to BOS remain largely unclear. We hypothesized that PGD, AR, DSA, and/or BOS can induce and release of exosomes into circulation, which may play a role in inducing rejection (<xref rid="fig1" ref-type="fig">Figure 1</xref>). In this communication, we will provide evidence for circulating exosomes originating from the transplanted lungs and will describe how these exosomes play a vital role in activating and perpetuating immune responses leading to BOS (<xref rid="appsec1" ref-type="sec">Video 1</xref>).<fig id="dfig1"><label>Video 1</label><caption><p>Exosomes in lung trasplant outcomes: Circulatory exosomes with lung-associated antigens are present in primary graft dysfunction, before development of donor-specific antibodies, acute rejection, and chronic rejection. Therefore, circulatory exosomes with lung-associated antigens are a novel mechanism of inducing immune responses leading to rejection of graft after lung transplantation. Video available at: <ext-link ext-link-type="uri" xlink:href="https://www.jtcvs.org/article/S0022-5223(19)30343-5/fulltext" id="interref0010u">https://www.jtcvs.org/article/S0022-5223(19)30343-5/fulltext</ext-link>.</p></caption><graphic xlink:href="fx2_lrg"></graphic></fig><fig id="fig1"><label>Figure 1</label><caption><p>Induction of exosomes may be a mechanism for development of chronic lung allograft rejection. Primary graft dysfunction (<italic>PGD</italic>), respiratory viral infection (<italic>RVI</italic>), donor-specific antibodies (<italic>DSA</italic>), and antibodies to self-antigens (<italic>Anti-SAgs</italic>) triggers stress on the endoplasmic reticulum, which releases the exosomes containing lung self-antigens and donor HLA. The persistence of exosomes, DSA, and antibodies to lung self-antigens leads release of more exosomes and activate the immune response, which may lead development of chronic rejection (bronchiolitis obliterans syndrome [<italic>BOS</italic>]). The transient exosomes do not activate immune responses, leading to rejection.</p></caption><graphic xlink:href="gr1_lrg"></graphic></fig></p><p id="p0035">Exosomes are membrane vesicles (40-100 nm in diameter) produced by endocytic pathways and secreted into body fluids. They contain membrane and cytosolic proteins and molecules essential for exosome biogenesis. Exosomes also have cell-specific components including proteins, messenger RNA, and microRNA (miRNA; <xref rid="fig2" ref-type="fig">Figure 2</xref>).<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Exosome-specific proteins include CD9, CD63, CD81, and CD82; proteins involved in exosome biogenesis include actin, annexins, tumor susceptibility gene 101, fibronectin-1, and vesicle-associated membrane protein 8.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Exosomes derived from cancer cells harbor dicer AGO2 and TRBP proteins, which can convert pre-miRNA into mature miRNA, leading to silencing of messenger RNA of target cells and initiate tumors. Hence, it has been proposed that differentially expressed protein and miRNA in cancer-derived exosomes may serve as potential biomarkers.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><fig id="fig2"><label>Figure 2</label><caption><p>Exosome release and its composition following lung transplantation. Exosomes are microvesicles produced by budding in early endosomes. These microvesicles either get degraded by lysosomes or release from the cells. Exosomes released after lung transplant contains lung self-antigens collagen type V and K alpha 1 tubulin, co-stimulatory molecules (CD80 and 86), exosomes markers (CD9, CD63 and CD81), MHC molecules, adhesion molecules, as well as messenger RNA (<italic>mRNA</italic>) and microRNA (<italic>miRNA</italic>). <italic>CD80 and 86</italic>, Costimulatory molecules 80 and 86; <italic>CD9</italic>, costimulatory molecule 9; <italic>CD63</italic>, costimulatory molecule 63; <italic>CD81</italic>, costimulatory molecule 81; <italic>MHC</italic>, major histocompatibility complex; <italic>miRNA</italic>, microRNA; <italic>mRNA</italic>, messenger RNA.</p></caption><graphic xlink:href="gr2_lrg"></graphic></fig></p><p id="p0040">Few reports describe the characteristics of exosomes found in bronchoalveolar lavage fluid (BALF) and serum samples after LTx.<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref> Gregson and colleagues<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> analyzed exosomal RNA collected from BALF following LTx and demonstrated that exosomes isolated from patients with acute cellular rejection are distinct, with their molecular signatures primarily involving immune activation in comparison with stable LTxRs. Recently, we demonstrated that exosomes isolated from sera and BALF from LTxRs diagnosed with AR or CR contain not only DSA but also lung SAgs Col-V and Kα1T<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> and also presented electron microscopic evidence for the expression of lung SAgs on the surface of exosomes. Exosomes isolated from stable LTxRs did not contain lung SAgs.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> These results suggest that exosomes induced during rejection of the transplanted lungs can induce immune responses, thus increasing the risk for development of BOS.</p><sec id="sec1"><title>Methods</title><sec id="sec1.1"><title>Patient Selection</title><p id="p0045">In 2017, 90 patients underwent LTx at Norton Thoracic Institute in Phoenix, Ariz. For this preliminary analysis, we identified 5 LTxRs diagnosed with PGD grade 3, 5 LTxRs with PGD grade 0, 15 LTxRs with symptomatic RVIs requiring intervention, 15 LTxRs without RVI and in stable condition, 10 LTxRs with AR, 10 without AR, 5 with de novo DSA, 5 without DSA, 10 diagnosed with BOS, and 10 stable LTxRs. All LTxRs selected for this study had undergone bilateral LTx and had no significant differences in demographics (eg, sex, age, reason for transplant, HLA matching, etc [<xref rid="tbl1" ref-type="table">Table 1</xref>]). For each group (ie, PGD, RVI, AR, DSA, and BOS) we identified time-matched controls for analysis. This study was approved by the human studies institutional review board of St Joseph's Hospital and Medical Center IRB committee (approval number PHXB-16-0027-10-18; date February 27, 2018).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Clinical and demographics data of lung transplant recipients</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Clinical features</th><th colspan="6">Groups<hr></hr></th></tr><tr><th>Group 1 (n = 45)<hr></hr></th><th>Group 2 (n = 5)<hr></hr></th><th>Group 3 (n = 10)<hr></hr></th><th>Group 4 (n = 5)<hr></hr></th><th>Group 5 (n = 10)<hr></hr></th><th>Group 6 (n = 15)<hr></hr></th></tr><tr><th>Stable/control</th><th>DSA patients</th><th>BOS patients</th><th>PGD3</th><th>Acute rejection</th><th>RVI</th></tr></thead><tbody><tr><td>Age, y</td><td>51 ± 13</td><td>51 ± 19</td><td>54 ± 15</td><td>44 ± 19</td><td>58 ± 13</td><td>57 ± 12</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Male</td><td align="char">35</td><td align="char">3</td><td align="char">6</td><td align="char">3</td><td align="char">6</td><td align="char">9</td></tr><tr><td> Female</td><td align="char">10</td><td align="char">2</td><td align="char">4</td><td align="char">2</td><td align="char">4</td><td align="char">6</td></tr><tr><td>Race</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> White</td><td align="char">40</td><td align="char">5</td><td align="char">8</td><td align="char">5</td><td align="char">9</td><td align="char">15</td></tr><tr><td> American Asian</td><td align="char">5</td><td align="char">0</td><td align="char">2</td><td align="char">0</td><td align="char">1</td><td align="char">0</td></tr><tr><td>End-stage disease</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> COPD</td><td align="char">14</td><td align="char">1</td><td align="char">3</td><td align="char">2</td><td align="char">5</td><td align="char">5</td></tr><tr><td> IPF</td><td align="char">7</td><td align="char">2</td><td align="char">3</td><td align="char">1</td><td align="char">2</td><td align="char">3</td></tr><tr><td> CF</td><td align="char">6</td><td align="char">2</td><td align="char">2</td><td align="char">0</td><td align="char">2</td><td align="char">2</td></tr><tr><td> Pulmonary fibrosis</td><td align="char">5</td><td align="char">0</td><td align="char">1</td><td align="char">1</td><td align="char">1</td><td align="char">2</td></tr><tr><td> ILD</td><td align="char">3</td><td align="char">0</td><td align="char">1</td><td align="char">1</td><td align="char">0</td><td align="char">1</td></tr><tr><td> others</td><td align="char">10</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">2</td></tr><tr><td>Mean time of sampling from LTx, mo</td><td>28 ± 8</td><td>16 ± 8</td><td>32 ± 10</td><td>38 ± 27 hr</td><td>16 ± 10</td><td>18 ± 12</td></tr><tr><td>Mismatch HLA</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> A</td><td>1.8 ± 0.5</td><td>2.1 ± 0.5</td><td>1.8 ± 0.5</td><td>1.4 ± 0.6</td><td>1.8 ± 0.5</td><td>1.7 ± 0.5</td></tr><tr><td> B</td><td>2.2 ± 0.8</td><td>1.7 ± 0.8</td><td>1.5 ± 0.5</td><td>1.3 ± 0.8</td><td>1.8 ± 0.8</td><td>1.2 ± 0.8</td></tr><tr><td> C</td><td>1.9 ± 0.9</td><td>1.5 ± 0.4</td><td>1.4 ± 0.3</td><td>1.6 ± 0.8</td><td>1.7 ± 0.5</td><td>1.5 ± 0.3</td></tr><tr><td>PGD</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Grade 1</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td> Grade 2</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td> Grade 3</td><td>–</td><td>–</td><td>–</td><td align="char">5</td><td>–</td><td>–</td></tr><tr><td>Acute rejection, n</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> A1</td><td>–</td><td>–</td><td>–</td><td>–</td><td align="char">2</td><td>–</td></tr><tr><td> A2</td><td>–</td><td>–</td><td>–</td><td>–</td><td align="char">8</td><td>–</td></tr><tr><td>Viral infection, n</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> RSV</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td align="char">6</td></tr><tr><td> Rhino virus</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td align="char">4</td></tr><tr><td> Corona virus</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td align="char">4</td></tr><tr><td> Parainfluenza</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td align="char">1</td></tr><tr><td>BOS</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Grade 1</td><td>–</td><td>–</td><td align="char">2</td><td>–</td><td>–</td><td>–</td></tr><tr><td> Grade 2</td><td>–</td><td>–</td><td align="char">2</td><td>–</td><td>–</td><td>–</td></tr><tr><td> Grade 3</td><td>–</td><td>–</td><td align="char">6</td><td>–</td><td>–</td><td>–</td></tr></tbody></table><table-wrap-foot><fn><p><italic>DSA</italic>, Donor-specific antibodies; <italic>BOS</italic>, bronchiolitis obliterans syndrome; <italic>PGD</italic>, primary graft dysfunction; <italic>RVI</italic>, symptomatic respiratory viral infection; <italic>COPD</italic>, chronic obstructive pulmonary disease; <italic>IPF</italic>, idiopathic pulmonary fibrosis; <italic>CF</italic>, cystic fibrosis; <italic>ILD</italic>, Interstitial lung disease; <italic>LTx</italic>, lung transplant; <italic>HLA</italic>, human leukocyte antigen; –, not applicable; <italic>RSV</italic>, respiratory syncytial virus.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec1.2"><title>Cell Culture and Treatment</title><p id="p0050">The KCC-266 airway epithelial cell line (AEC) was developed in our laboratory from a lung airway biopsy, immortalized by transfection with the pRSV-Tag plasmid, and cultured in RPMI-1640 medium supplemented with bovine serum albumin (2%), L-glutamine (2 mM), nonessential amino acids (100 μM), HEPES (25 mM), sodium pyruvate (1 mM), penicillin (100 U/mL), and streptomycin (0.1 mg/mL) as previously described.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> The AECs (1 × 10<sup>6</sup> cells) were cultured for 24 hours in the presence of the anti-HLA (Hi PRA, 1:50 dilution), and Abs to lung SAgs (Col-V and Kα1T) at 20 μg/mL. Cell supernatant was collected from KCC-266 after 24 hours for exosome isolation. Cells without treatment were used as control.</p></sec><sec id="sec1.3"><title>Exosome Isolation</title><p id="p0055">Circulating exosomes from LTxRs were isolated using the Total Exosome Isolation Kit (Invitrogen by Thermo Fisher Scientific, Waltham, Mass) as per manufacturer protocol. To summarize in brief, plasma was centrifuged at 2000<italic>g</italic> and 10,000<italic>g</italic> for 20 minutes to remove debris. Plasma was diluted with phosphate-buffered saline (PBS, 0.5 volume) and exosomes precipitation solution (0.2 volume), incubated for 10 minutes, and then centrifuged at 10,000g for 5 minutes at room temperature. The exosome pellet was dissolved in PBS and used for all analysis.</p><p id="p0060">Exosomes from culture media were isolated using ultracentrifugation. In brief; cell supernatant was centrifuged for 30 minutes at 3000<italic>g</italic> and 10,000<italic>g</italic> to remove cells and debris. The supernatant was then centrifuged at 100,000<italic>g</italic> for 120 minutes to isolate exosomes. Exosome pellets were stored at −80°C for experiments.</p></sec><sec id="sec1.4"><title>Enzyme-Linked Immunosorbent Assay for HLA</title><p id="p0065">We performed enzyme-linked immunosorbent assay to detect donor HLA in exosomes as described by Logozzi and colleagues<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> with minor modifications. A 96-well plate was coated with anti-CD9 Ab (BioLegend, San Diego, Calif) and incubated overnight at 4°C. The plate was washed with PBS and blocked with 0.5% bovine serum albumin in PBS (blocking buffer) and incubated with exosomes (1 mg/mL) isolated from the plasma of LTxRs overnight at 37°C. Murine mAbs to HLA2 or A3 were added and incubated for 2 hours at room temperature, followed by secondary Ab goat anti-mouse conjugated with horseradish peroxidase. After 3 washes with PBS, a reaction was developed with chemiluminescent reagent (MilliporeSigma, Burlington, Mass) and the reaction was stopped with 0.1 N HCl. Optical density was measured at 450 nm.</p></sec><sec id="sec1.5"><title>Western Blot Analysis</title><p id="p0070">Isolated exosomes were used to analyze the expression of lung-associated SAgs (Col-V and Kα1T), costimulatory molecules (costimulatory molecule 80 [CD80] and costimulatory molecule 86 [CD86]), transcription factor (nuclear factor kappa-light-chain-enhancer of activated B cells [NF-kB], hypoxia-inducible factor 1α [HIF-1α], and Class II Major Histocompatibility Complex Transactivator [CIITA]), major histocompatibility complex (MHC) class II, adhesion molecules (intercellular adhesion molecule [ICAM], vascular cell adhesion molecule [VCAM]), and 20S Proteasome using western blot with specific Abs. Loading control CD9 was used. Protein (10 μg) was resolved and transferred to a polyvinylidene difluoride membrane. The membrane was blocked with blocking buffer. Specific primary Abs and corresponding secondary Abs goat anti-rabbit and mouse conjugated with horseradish peroxidase were used to detect expression of proteins. Enhanced chemiluminescent substrate (MilliporeSigma) was used to develop blots, and imaging was done using Odyssey CLx imaging system (LI-COR Biosciences, Lincoln, Neb). Band intensity was quantified by Image J Software (National Institutes of Health, Bethesda, Md).</p><p id="p0075">To determine lung SAgs Col-V and Kα1T by western blot, rabbit anti-Col-V (Abcam, Inc, Cambridge, United Kingdom) and mouse anti-Kα1T (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) Abs were used.</p><p id="p0080">MHC class II molecules were detected by western blot using Abs to MHC class II (Abcam, Inc). Costimulatory molecules, CD80 and CD86, were detected using rabbit anti, CD 80 and 86 (Abcam, Inc).</p><p id="p0085">Transcription factors NF-KB, HIF-1α, and CIITA were identified by western blot using Abs specific to NF-kB (Cell Signaling Technology, Inc, Danvers, Mass), HIF-1α, and CIITA (Abcam, Inc). Adhesion molecules ICAM and VCAM were detected by western blot using mouse anti Abs to ICAM and VCAM (BioLegend). 20S proteasome, α3 subunit in the exosomes were detected using anti-mouse to α3 subunit 20s proteasomes (Santa Cruz Biotechnology). ER stress markers (Eif2α and PERK) were analyzed by immunoblot using Abs specific to the Eif2α and PERK.</p></sec><sec id="sec1.6"><title>Statistical Analysis</title><p id="p0090">Statistical analysis was calculated with GraphPad Prism 6 (GraphPad Software Inc, La Jolla, Calif). Statistical data were expressed as mean ± standard deviation. We used <italic>t</italic>-test 2-tailed nonparametric (Mann–Whitney <italic>U</italic> test) to detect statistical significance. <italic>P</italic> values less than .05 were considered statistically significant in each analysis. Image J software was used to quantify optical density of blot. Fold changes are based on experiment versus control of each group.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Severe PGD3 After LTx Induces Exosomes From the Transplanted Organ, Which Are Released Into the Circulation and Contain Lung SAgs Kα1T and Col-V</title><p id="p0095">Exosomes were isolated from the plasma of 5 LTxRs with PGD3 and 5 LTxRs without PGD (ie, PGD0) diagnosed according to the International Society for Heart and Lung Transplantation guidelines. The results, presented in <xref rid="fig3" ref-type="fig">Figure 3</xref>, <italic>A</italic>, demonstrate exosomes present in the circulation with specific marker CD9, although the quantity is greater in the plasma of LTxRs with PGD3 than in the patients with PGD0. However, only LTxRs diagnosed with PGD3 induced circulating exosomes with lung SAgs Kα1T and Col-V (illustration of 2/5 patient data). Semiquantitative analysis by densitometry, shown in <xref rid="fig3" ref-type="fig">Figure 3</xref>, <italic>B</italic>, demonstrates that exosomes isolated from LTxRs with PGD3 have significantly greater levels of both lung SAgs Col-V (2.29-fold increase, <italic>P</italic> = .0087) and Kα1T (3.25-fold increase, <italic>P</italic> = .0087) than patients with PGD0.<fig id="fig3"><label>Figure 3</label><caption><p>PGD3 exosomes contain Col-V and Kα1T. Exosomes were isolated from the plasma of LTxRs with PGD3 (n = 5) and LTxRs without PGD (PGD0, n = 5). Exosomes were subjected to immunoblot. A, Western blot shows that exosomes from LTxRs with PGD3 contain lung SAgs Col-V and Kα1T but not with PGD0. B, Densitometry analysis showed significant increases in Col-V (<italic>P</italic> = .0087) and Kα1T (<italic>P</italic> = .0087) levels in PGD3 patients. CD9 was used as loading control marker. Data represented as <italic>box-whisker graph</italic> (Col-V: PGD3: median 1.028-fold change, interquartile range 0.954- to 2.111-fold change, PGD0: median 0.683-fold change, interquartile range 0.209- to 0.953-fold change; Kα1T: PGD3: median 1.507-fold change, interquartile range 0.543- to 2.497-fold change; PGD0: median 0.453-fold change, interquartile range 0.322- to 0.716-fold change). The experiment was done twice. <italic>PGD</italic>, Primary graft dysfunction; <italic>Col-V</italic>, collagen V; <italic>Kα1T</italic>, K alpha 1 tubulin; <italic>CD9</italic>, costimulatory molecule 9.</p></caption><graphic xlink:href="gr3_lrg"></graphic></fig></p></sec><sec id="sec2.2"><title>LTxRs Diagnosed With AR Induce Exosomes With Lung SAgs That Are Detectable in the Circulation</title><p id="p0100">To demonstrate that AR may also induce exosomes from the transplanted organ, we isolated exosomes from 10 LTxRs diagnosed with AR and time-matched 10 stable LTxRs. Exosomes with specific marker CD9 were present in similar quantities both in LTxRs with rejection (representative 2/10 patients’ data, <xref rid="fig4" ref-type="fig">Figure 4</xref>, <italic>A</italic>) and in those without rejection (representative of 2/10 stable patients), only the LTxRs diagnosed with AR demonstrated the presence of lung SAgs Col-V and Kα1T (<xref rid="fig4" ref-type="fig">Figure 4</xref>, <italic>A</italic>). <xref rid="fig4" ref-type="fig">Figure 4</xref>, <italic>B</italic>, represents the densitometry results of 10 LTxRs diagnosed with rejection and 10 stable LTxRs; the exosomes isolated from LTxRs with AR had significantly greater levels of both lung SAgs Col-V (9.46-fold increase, <italic>P</italic> < .0001) and Kα1T (12.6-fold increase, <italic>P</italic> < .0001) than those isolated from stable LTxRs.<fig id="fig4"><label>Figure 4</label><caption><p>Exosomes from LTxRs with AR show lung SAgs Col-V and Kα1T. Exosomes were isolated from plasma of LTxRs with AR (n = 10) and from stable LTxRs (n = 10) and were subjected to immunoblot. A, Western blot demonstrates that exosomes from LTxRs with AR contain lung SAgs Col-V and Kα1T, but these SAgs were not present in stable LTxRs. B, Densitometry analysis shows significant increase of Col-V (<italic>P</italic> ≤ .0001) and Kα1T (<italic>P</italic> ≤ .0001) in exosomes isolated from LTxRs with AR. CD9 was used as loading control marker. <italic>Box-whisker graph</italic> signified Col-V: AR median: 0.979-fold change (interquartile range, 0.797- to 2.125-fold change), median of stable, 0.114-fold change (interquartile range 0.078- to 0.221-fold change); Kα1T: AR: median 0.900-fold change (interquartile range 0.302- to 1.691-fold change) S: median 0.075-fold change (interquartile range 0.028- to 0.138-fold change). The experiment was performed in duplicate. <italic>AR</italic>, Acute rejection; <italic>S</italic>, stable; <italic>Col-V</italic>, collagen V; <italic>Kα1T</italic>, K alpha 1 tubulin; <italic>CD9</italic>, costimulatory molecule 9.</p></caption><graphic xlink:href="gr4_lrg"></graphic></fig></p></sec><sec id="sec2.3"><title>Exosomes Isolated From LTxRs With Viral Infection Contain SAgs</title><p id="p0105">To determine whether symptomatic RVI can also lead to exosome induction from the transplanted organ, we analyzed 15 patients diagnosed with symptomatic RVI and 15 stable patients with no clinical signs of RVI. As shown previously, both groups had similar levels of exosomes containing specific marker CD9; however, only those with symptomatic RVI demonstrated exosomes containing lung SAgs Col-V and Kα1T (<xref rid="fig5" ref-type="fig">Figure 5</xref>, <italic>A</italic>). <xref rid="fig5" ref-type="fig">Figure 5</xref>, <italic>B</italic>, presents results of semiquantitation using densitometry of all patients (15 with symptomatic RVI and 15 stable without RVI); levels of exosomes with lung SAgs were significantly increased in patients with symptomatic RVI compared with stable patients (9.92-fold increase in lung SAg Col-V, <italic>P</italic> = .0079; 4-fold increase in Kα1T, <italic>P</italic> = .0079).<fig id="fig5"><label>Figure 5</label><caption><p>Presence of lung SAgs in exosomes isolated from LTxRs with RVI. Exosomes were isolated from plasma of LTxRs diagnosed with RVI (n = 15) and from stable LTxRs (n = 15) and were subjected to immunoblot. A, Western blot demonstrates that exosomes from LTxRs with viral, symptomatic RVI have lung SAgs Col-V and Kα1T; exosomes isolated from stable LTxRs do not. B, Densitometry analysis showed significant increase in Col-V (<italic>P</italic> = .0079) and Kα1T (<italic>P</italic> = .0079) levels in LTxRs with RVI. CD9 was used as loading control marker. <italic>Box-whisker plot</italic> represents median value for each group Col V: RVI: median 1.364-fold change (interquartile range, 0.787- to 1.560-fold change): S: median 0.135-fold change (interquartile range, 0.076- to 0.169-fold); Kα1T: RVI: median 0.536-fold change (interquartile range, 0.337- to 0.838-fold): Stable median, 0.124-fold change (interquartile range, 0.094- to 0.200-fold). The experiment was done twice. <italic>RVI</italic>, Symptomatic respiratory viral infection; <italic>S</italic>, stable; <italic>Col-V</italic>, collagen V; <italic>Kα1T</italic>, K alpha 1 tubulin; <italic>CD9</italic>, costimulatory molecule 9.</p></caption><graphic xlink:href="gr5_lrg"></graphic></fig></p></sec><sec id="sec2.4"><title>De Novo DSA Development Releases Exosomes With Lung SAgs</title><p id="p0110">De novo development of Abs to DSA is generally thought to increase the risk for development of both AR and CR following LTx. To determine whether early development of DSA following LTx can induce circulating exosomes, we selected 5 LTxRs who developed DSA within 3 months of transplant and 5 LTxRs without DSA matched for duration following transplant. As shown in <xref rid="fig6" ref-type="fig">Figure 6</xref>, <italic>A</italic>, exosomes isolated from LTxRs who developed de novo DSA contained greater levels of lung SAgs Col-V and Kα1T than LTxRs without demonstrable DSA. Semiquantitation by densitometry of 5 LTxRs with DSA and 5 without DSA (<xref rid="fig6" ref-type="fig">Figure 6</xref>, <italic>B</italic>) demonstrated significantly greater levels of exosomes containing lung SAgs in LTxRs with DSA than in those without (1.47-fold increase of lung SAg Col-V, <italic>P</italic> = .0286; 1.56-fold increase in Kα1T, <italic>P</italic> = .0159).<fig id="fig6"><label>Figure 6</label><caption><p>DSA + LTxRs release lung SAgs containing exosomes. Exosomes were isolated from the plasma of LTxRs diagnosed with DSA (n = 5) and from stable LTxRs (n = 5) and were subjected to immunoblot. A, Western blot demonstrates that DSA + LTxRs release exosomes with lung SAgs Col-V and Kα1T, but stable LTxRs do not. B, Densitometry analysis shows significant increase in Col-V (<italic>P</italic> = .0286) and Kα1T (<italic>P</italic> = .0159). CD9 was used as loading control marker. Data indicated as <italic>box-whisker graph</italic> (Col-V: DSA+: median 0.922-fold change, interquartile range 0.832- to 1.454-fold; DSA–: median 0.709-fold change, interquartile range 0.625- to 0.767-fold. Kα1T: DSA+: median 1.005-fold change, interquartile range 0.844- to 1.185-fold; DSA–: median 0.779-fold change, interquartile range 0.313- to 0.849-fold). The experiment was repeated 2 times. <italic>DSA+</italic>, Donor HLA–specific antibodies positive; <italic>DSA−</italic>, donor HLA–specific antibodies negative; <italic>D</italic>, donor-specific antibodies; <italic>Col-V</italic>, collagen V; <italic>Kα1T</italic>, K alpha 1 tubulin; <italic>CD9</italic>, costimulatory molecule 9.</p></caption><graphic xlink:href="gr6_lrg"></graphic></fig></p><p id="p0115">To determine whether binding of Abs to HLA or lung SAgs can induce exosomes in vitro, we incubated AECs with anti-HLA or anti-lung SAgs. Exosomes were isolated from the supernatant after overnight incubation with Abs. The exosomes contained lung SAgs, demonstrating that ligation by specific Abs can result in the induction and release of exosomes (<xref rid="fig7" ref-type="fig">Figure 7</xref>). Control cells without addition of antibodies did not induce exosomes containing lung self-antigens into the supernatants.<fig id="fig7"><label>Figure 7</label><caption><p>Anti–HLA (HiPRA) or Abs to SAgs Col-V and Kα1T induce exosomes with lung SAgs. Exosome were isolated from AECs treated with anti–HLA or Abs to SAgs and protein was isolated and subjected to western blot. A, Western blot data show that treatment with anti-HLA and Abs to SAgs induced release of exosomes containing SAgs Col-V and Kα1T. CD9 was used as loading control. B, Densitometry analysis shows significant increase in Col-V expression after treatment with HLA antibodies and antibodies to SAgs. The experiment was done twice. <italic>HLA</italic>, Human leukocyte antigen; <italic>Col-V</italic>, collagen V; <italic>CD9</italic>, costimulatory molecule 9; <italic>Kα1T</italic>, K alpha 1 tubulin; <italic>Abs</italic>, antibodies.</p></caption><graphic xlink:href="gr7_lrg"></graphic></fig></p></sec><sec id="sec2.5"><title>Release of Lung SAgs Containing Exosomes in LTxRs Diagnosed With BOS</title><p id="p0120">To determine whether LTxRs diagnosed with BOS also induce circulatory exosomes with lung Sags, we identified 10 LTxRs diagnosed with BOS as per International Society for Heart and Lung Transplantation guidelines and 10 stable, time-matched LTxRs. Circulating exosomes were isolated from the plasma at or around the time of diagnosis. Purified exosomes were subjected to western blot for presence of lung SAgs. As shown in <xref rid="fig8" ref-type="fig">Figure 8</xref>, <italic>A</italic>, exosomes isolated from LTxRs diagnosed with BOS contained lung SAgs. Densitometry analysis demonstrated significantly greater levels of exosomes with lung SAgs Col-V and Kα1T in the exosomes isolated from LTxRs with BOS than in those isolated from stable LTxRs (2.08-fold change in the levels of Col-V, <italic>P</italic> = .0043; 2.8-fold change in Kα1T, <italic>P</italic> = .0173; <xref rid="fig8" ref-type="fig">Figure 8</xref>, <italic>B</italic>).<fig id="fig8"><label>Figure 8</label><caption><p>Exosomes isolated from LTxRs with bronchiolitis obliterans syndrome contain lung SAgs Col-V and Kα1T. Exosomes were isolated from plasma of LTxRs with bronchiolitis obliterans syndrome (n = 10) and from stable LTxRs (n = 10) and were subjected to immunoblot. A, Western blot demonstrates that exosomes from LTxRs with bronchiolitis obliterans syndrome contain lung SAgs Col-V and Kα1T, but exosomes from stable LTxRs do not. B, Densitometry analysis shows significant increase in Col-V (<italic>P</italic> = .043) and Kα1T (<italic>P</italic> = .0173) in exosomes from LTxRs with bronchiolitis obliterans syndrome but not in exosomes from stable LTxRs. CD9 was used as loading control marker. <italic>Box-whisker graph</italic> signified median of each group with lower to higher range: Col-V: bronchiolitis obliterans syndrome: median 1.511-fold change (interquartile range 0.962- to 2.111-fold change), stable median, 0.765-fold change (interquartile range, 0.628- to 0.953-fold change). Kα1T: bronchiolitis obliterans syndrome: median 1.507-fold change (interquartile range 0.543- to 2.497-fold change), stable median, 0.557-fold change (interquartile range 0.429- to 0.716-fold change). The experiment was carried out in duplicate. <italic>B</italic>, Bronchiolitis obliterans syndrome; <italic>S</italic>, stable; <italic>Col-V</italic>, collagen V; <italic>Kα1T</italic>, K alpha 1 tubulin; <italic>CD9</italic>, costimulatory molecule 9; <italic>BOS</italic>, bronchiolitis obliterans syndrome.</p></caption><graphic xlink:href="gr8_lrg"></graphic></fig></p></sec><sec id="sec2.6"><title>Exosomes Isolated From LTxRs With PGD, Symptomatic RVI, AR, DSA, and BOS Contain Not Only Allo- and Lung SAgs but Also Contain Immunoregulatory Molecules, Proinflammatory Transcription Factors, Proteasome, and Stress Markers</title><p id="p0125">Circulating exosomes isolated from LTxRs with PGD3, PGD0, AR, DSA+, DSA−, BOS, and from stable LTxRs were analyzed by western blot using specific Abs to MHC class II molecule; co-stimulatory molecules CD80 and CD86; transcription factors NF-κB, CIITA, and HIFα; 20S proteasome; and stress markers eIF2alpha and PERK. The results, which are presented in <xref rid="tbl1" ref-type="table">Table 1</xref>, summarize our findings: namely, that exosomes from all of the aforementioned post-LTx clinical conditions contain not only allo- and lung SAgs, but also important immunoregulatory molecules and stress markers. It is of interest that costimulatory molecules CD80 and CD86 were notably absent in the exosomes isolated from patients with symptomatic RVI. Overall, data presented in <xref rid="tbl2" ref-type="table">Table 2</xref>suggest that exosomes present in the circulation have many of the molecules necessary to augment immunogenicity, which can lead to CLAD.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Characteristics of exosomes isolated from PGD3 symptomatic respiratory viral infection, acute rejection, BOS, and DSA lung transplant recipients</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"></th><th colspan="3">Costimulatory molecules<hr></hr></th><th colspan="3">Transcription factor<hr></hr></th><th colspan="2">Adhesion molecules<hr></hr></th><th>20S proteasome<hr></hr></th><th colspan="2">ER stress markers<hr></hr></th><th rowspan="2">Donor HLA</th></tr><tr><th>MHC II</th><th>CD80</th><th>CD86</th><th>CIITA</th><th>NF-κB</th><th>HIF-1α</th><th>ICAM</th><th>VCAM</th><th>α-subunit</th><th>eIF2α</th><th>PERK</th></tr></thead><tbody><tr><td>PGD-3</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td>ND</td><td>ND</td><td align="char">+</td></tr><tr><td>Symptomatic respiratory viral infection</td><td align="char">+</td><td>–</td><td>–</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td>ND</td><td>ND</td><td align="char">+</td></tr><tr><td>Acute rejection</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td>ND</td><td>ND</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td></tr><tr><td>BOS</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td><td align="char">+</td></tr><tr><td>DSA</td><td align="char">+</td><td>ND</td><td>ND</td><td align="char">+</td><td align="char">+</td><td>ND</td><td>ND</td><td>ND</td><td align="char">+</td><td>ND</td><td>ND</td><td align="char">+</td></tr></tbody></table><table-wrap-foot><fn><p><italic>ER</italic>, Endoplasmic reticulum; <italic>HLA</italic>, human leukocyte antigen; <italic>MHC-II</italic>, major histocompatibility complex–class II molecule; <italic>CD80</italic>, costimulatory molecule 80; <italic>CD86</italic>, costimulatory molecule 86; <italic>CIITA</italic>, Class II Major Histocompatibility Complex Transactivator; <italic>NF-κB</italic>, nuclear factor kappa-light-chain-enhancer of activated B cells; <italic>HIF-1α</italic>, hypoxia-inducible factor 1-alpha; <italic>ICAM</italic>, intercellular adhesion molecule; <italic>VCAM</italic>, vascular cell adhesion molecule; <italic>eIF-2α</italic>, eukaryotic Initiation Factor 2 alpha; <italic>PERK</italic>, protein kinase R–like endoplasmic reticulum kinase; <italic>PGD</italic>, Primary graft dysfunction; +, present; <italic>ND</italic>, not done; –, absent; <italic>BOS</italic>, bronchiolitis obliterans syndrome; <italic>DSA</italic>, donor-specific antibodies.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0130">Risk factors associated with CLAD include PGD, RVI, AR, and de novo development of Abs to DSA. Our goal was to define a common denominator in LTxRs diagnosed with PGD, RVI, AR, or DSA that triggers immune responses that can lead to BOS. In this communication, we present a unifying, biologically plausible mechanistic link between PGD, RVI, and alloimmune responses that can result in CLAD (ie, induction and release of circulating exosomes with lung SAgs, allo-antigens, and immune-stimulatory molecules).</p><p id="p0135">Gregson and colleagues<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> analyzed exosomal RNA from BALF following LTx and demonstrated that exosomes isolated from patients with acute cellular rejection are distinct, with their molecular signatures primarily involving immune activation in comparison with stable LTxRs. BALF cell pellet and exosome transcriptome in patients with AR and CR after LTx have demonstrated molecular signatures primarily involving innate and adaptive cytotoxic immune responses.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Recently, we demonstrated that exosomes isolated from sera and BALF of LTxRs diagnosed with AR or CR contains not only DSA but also the lung SAgs Col-V and Kα1T. These results suggest that exosomes induced during rejection of the transplanted lungs can induce immune responses, thereby increasing the risk of development of BOS.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Heart and skin transplant models in mice have shown that donor-derived exosomes containing donor MHC can cross-dress recipient antigen-presenting cells, leading to activation and proliferation of alloreactive T cells via the semi-direct pathway of allorecognition.<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref></p><p id="p0140">Previous studies from our laboratory have shown that Abs to HLA and/or tissue-restricted SAgs develop months before lung allograft rejection, suggesting a pathogenic role for Abs in the development of BOS following LTx.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Furthermore, in most patients who develop either Abs to HLA or Abs to lung SAgs have a greater chance of developing Abs to each other, suggesting spreading of immune responses resulting in CLAD. However, the mechanism leading to the spreading was unclear, as HLA molecules and lung SAgs are encoded by different genes in different chromosomes. The results presented here and studies in murine models strongly support an important role for exosomes in inducing and spreading of immune responses leading to CLAD.<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref></p><p id="p0145">In this study, we demonstrated that increased expression of Col-V and Kα1T in circulating exosomes isolated from LTxRs developed PGD, RVI, AR, DSA, and BOS. The exosomes also contained MHC class II molecules, its transcription factor CIITA, and proinflammatory transcription factors such as NF-κβ and HIFα and 20S proteosome. Furthermore, exosomes from LTxRs with PGD3, AR, and BOS contained co-stimulatory molecules (CD80, 86), supporting the theory that the exosomes can be highly immunogenic. An important role for 20S proteasome in augmenting immune responses by exosomes was recently presented by Dieude and colleagues.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> They showed that humoral immune responses in mice to the kidney SAg perlecan are induced by the presence of 20s proteasomes within the exosomes, and removal of the activity of proteasome abrogated the immune responses to perlecan.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> We demonstrated that mice immunized with exosomes isolated from LTxRs diagnosed with BOS induced development of both humoral and cellular immune responses to Col-V and Kα1T, but not in stable patients.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> In addition, distinct differences were noted in exosomes between BOS and stable LTxRs with respect to their immunogenicity.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref></p><p id="p0150">Using a syngeneic cardiac transplant model, Sharma and colleagues<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> demonstrated that Abs to cardiac myosin administered immediately following syngeneic murine heterotopic cardiac transplant results in graft failure, and the released exosomes contain cardiac myosin and vimentin. Further, this study demonstrated an important role for exosomes in graft failure, as immunization with exosomes isolated from sera following graft failure also developed Abs to cardiac myosin and vimentin and resulted in graft loss 8 days after syngeneic cardiac transplant.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Following human renal transplantation, there is evidence for release of increased levels of circulating C4d<sup>+</sup> plasma endothelial microvesicles that correlated with antibody-mediated AR.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> This indicates that Abs developed de novo can induce exosomes and may participate in antibody-mediated rejection.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref></p><p id="p0155">One of the major limitations of this study is relatively small number of patients analyzed for each clinical condition and not analyzing various sub categories. Future studies are needed to with exosomes isolated from different grades of PGD, AR, as well as BOS.</p><p id="p0160">In conclusion, our results demonstrated that circulating exosomes are induced and can be easily isolated from LTxRs diagnosed with PGD, RVI, AR, DSA, and BOS. These circulating exosomes are distinct in their properties compared with stable LTxRs with respect to the presence of tissue-associated lung SAgs Col-V and Kα1T, co-stimulatory molecules, MHC class II, its transcription factor CIITA, proinflammatory transcription factors including NF-κB, HIFα, and 20S proteasome. We propose that the induction of circulating exosomes is an important unifying mechanistic link between PGD, RVI, and alloimmune responses that increase the risk for the development of CLAD following LTx.</p><sec id="sec3.1"><title>Conflict of Interest Statement</title><p id="p0165">Authors have nothing to disclose with regard to commercial support.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Arcasoy</surname><given-names>S.M.</given-names></name><name><surname>Kotloff</surname><given-names>R.M.</given-names></name></person-group><article-title>Lung transplantation</article-title><source>N Eng J Med</source><volume>340</volume><year>1999</year><fpage>1081</fpage><lpage>1091</lpage></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Trulock</surname><given-names>E.P.</given-names></name><name><surname>Edwards</surname><given-names>L.B.</given-names></name><name><surname>Taylor</surname><given-names>D.O.</given-names></name><name><surname>Boucek</surname><given-names>M.M.</given-names></name><name><surname>Keck</surname><given-names>B.M.</given-names></name><name><surname>Hertz</surname><given-names>M.I.</given-names></name></person-group><article-title>Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report—2006</article-title><source>J Heart Lung Transplant</source><volume>25</volume><year>2006</year><fpage>880</fpage><lpage>892</lpage><pub-id pub-id-type="pmid">16890108</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Estenne</surname><given-names>M.</given-names></name><name><surname>Hertz</surname><given-names>M.I.</given-names></name></person-group><article-title>Bronchiolitis obliterans after human lung transplantation</article-title><source>Am J Respir Crit Care Med</source><volume>166</volume><year>2003</year><fpage>440</fpage><lpage>444</lpage></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Jaramillo</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>M.A.</given-names></name><name><surname>Phelan</surname><given-names>D.</given-names></name><name><surname>Sundaresan</surname><given-names>S.</given-names></name><name><surname>Trulock</surname><given-names>E.P.</given-names></name><name><surname>Lynch</surname><given-names>J.P.</given-names></name></person-group><article-title>Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation</article-title><source>Transplantation</source><volume>67</volume><year>1999</year><fpage>1155</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">10232567</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Hachem</surname><given-names>R.R.</given-names></name><name><surname>Yusen</surname><given-names>R.D.</given-names></name><name><surname>Meyers</surname><given-names>B.F.</given-names></name><name><surname>Aloush</surname><given-names>A.A.</given-names></name><name><surname>Mohanakumar</surname><given-names>T.</given-names></name><name><surname>Patterson</surname><given-names>G.A.</given-names></name></person-group><article-title>Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation</article-title><source>J Heart Lung Transplant</source><volume>29</volume><year>2010</year><fpage>973</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">20558084</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Bharat</surname><given-names>A.</given-names></name><name><surname>Saini</surname><given-names>D.</given-names></name><name><surname>Steward</surname><given-names>N.</given-names></name><name><surname>Hachem</surname><given-names>R.</given-names></name><name><surname>Trulock</surname><given-names>E.P.</given-names></name><name><surname>Patterson</surname><given-names>G.A.</given-names></name></person-group><article-title>Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection</article-title><source>Ann Thorac Surg</source><volume>90</volume><year>2010</year><fpage>1094</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">20868794</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Bharat</surname><given-names>A.</given-names></name><name><surname>Kuo</surname><given-names>E.</given-names></name><name><surname>Saini</surname><given-names>D.</given-names></name><name><surname>Steward</surname><given-names>N.</given-names></name><name><surname>Hachem</surname><given-names>R.</given-names></name><name><surname>Trulock</surname><given-names>E.P.</given-names></name></person-group><article-title>Respiratory virus-induced dysregulation of T-regulatory cells leads to chronic rejection</article-title><source>Ann Thorac Surg</source><volume>90</volume><year>2010</year><fpage>1637</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">20971279</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Almaghrabi</surname><given-names>R.S.</given-names></name><name><surname>Omrani</surname><given-names>A.S.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Cytomegalovirus infection in lung transplant recipients</article-title><source>Exp Rev Respir Med</source><volume>11</volume><year>2017</year><fpage>377</fpage><lpage>383</lpage></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>C.E.</given-names></name><name><surname>Mohanakumar</surname><given-names>T.</given-names></name><name><surname>Limaye</surname><given-names>A.P.</given-names></name></person-group><article-title>Respiratory virus infections and chronic lung allograft dysfunction: assessment of virology determinants</article-title><source>J Heart Lung Transplant</source><volume>35</volume><year>2016</year><fpage>946</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">27235268</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>P.R.</given-names></name><name><surname>Carpenter</surname><given-names>D.</given-names></name><name><surname>Ritter</surname><given-names>J.</given-names></name><name><surname>Yusen</surname><given-names>R.D.</given-names></name><name><surname>Witt</surname><given-names>C.A.</given-names></name><name><surname>Byers</surname><given-names>D.E.</given-names></name></person-group><article-title>The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation</article-title><source>Am J Transplant</source><volume>18</volume><year>2018</year><fpage>936</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">28992372</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Steward</surname><given-names>N.</given-names></name><name><surname>Sweet</surname><given-names>S.C.</given-names></name><name><surname>Danziger-Isakov</surname><given-names>L.</given-names></name><name><surname>Heeger</surname><given-names>P.S.</given-names></name></person-group><article-title>Role of circulating microRNAs in the immunopathogenesis of rejection after pediatric lung transplantation</article-title><source>Transplantation</source><volume>101</volume><year>2017</year><fpage>2461</fpage><lpage>2468</lpage><pub-id pub-id-type="pmid">27941431</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>R.J.</given-names></name><name><surname>Jensen</surname><given-names>S.S.</given-names></name><name><surname>Lim</surname><given-names>J.W.E.</given-names></name></person-group><article-title>Proteomic profiling of exosomes: current perspectives</article-title><source>Proteomics</source><volume>8</volume><year>2008</year><fpage>4083</fpage><lpage>4099</lpage><pub-id pub-id-type="pmid">18780348</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Raimondo</surname><given-names>F.</given-names></name><name><surname>Morosi</surname><given-names>L.</given-names></name><name><surname>Chinello</surname><given-names>C.</given-names></name><name><surname>Magni</surname><given-names>F.</given-names></name><name><surname>Pitto</surname><given-names>M.</given-names></name></person-group><article-title>Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery</article-title><source>Proteomics</source><volume>11</volume><year>2011</year><fpage>709</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">21241021</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Melo</surname><given-names>S.A.</given-names></name><name><surname>Sugimoto</surname><given-names>H.</given-names></name><name><surname>O'Connell</surname><given-names>J.T.</given-names></name><name><surname>Kato</surname><given-names>N.</given-names></name><name><surname>Villanueva</surname><given-names>A.</given-names></name><name><surname>Vidal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis</article-title><source>Cancer Cell</source><volume>26</volume><year>2014</year><fpage>707</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">25446899</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Gregson</surname><given-names>A.L.</given-names></name><name><surname>Hoji</surname><given-names>A.</given-names></name><name><surname>Injean</surname><given-names>P.</given-names></name><name><surname>Poynter</surname><given-names>S.T.</given-names></name><name><surname>Briones</surname><given-names>C.</given-names></name><name><surname>Palchevskiy</surname><given-names>V.</given-names></name></person-group><article-title>Altered exosomal RNA profiles in bronchoalveolar lavage from lung transplants with acute rejection</article-title><source>Am J Respir Crit Care Med</source><volume>192</volume><year>2015</year><fpage>1490</fpage><lpage>1503</lpage><pub-id pub-id-type="pmid">26308930</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Gunasekaran</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Nayak</surname><given-names>D.K.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Hachem</surname><given-names>R.</given-names></name><name><surname>Walia</surname><given-names>R.</given-names></name></person-group><article-title>Donor-derived exosomes with lung self-antigens in human lung allograft rejection</article-title><source>Am J Transplant</source><volume>17</volume><year>2017</year><fpage>474</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">27278097</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Jaramillo</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>C.R.</given-names></name><name><surname>Maruyama</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Patterson</surname><given-names>G.A.</given-names></name><name><surname>Mohanakumar</surname><given-names>T.</given-names></name></person-group><article-title>Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome</article-title><source>Hum Immunol</source><volume>64</volume><year>2003</year><fpage>521</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">12691702</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Logozzi</surname><given-names>M.</given-names></name><name><surname>Angelini</surname><given-names>D.F.</given-names></name><name><surname>Iessi</surname><given-names>E.</given-names></name><name><surname>Mizzoni</surname><given-names>D.</given-names></name><name><surname>DiRaimo</surname><given-names>R.</given-names></name><name><surname>Federic</surname><given-names>C.</given-names></name></person-group><article-title>Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients</article-title><source>Cancer Lett</source><volume>403</volume><year>2017</year><fpage>318</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">28694142</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Weigt</surname><given-names>S.S.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Palchevsky</surname><given-names>V.</given-names></name><name><surname>Gregson</surname><given-names>A.L.</given-names></name><name><surname>Patel</surname><given-names>N.</given-names></name><name><surname>DerHovanessian</surname><given-names>A.</given-names></name></person-group><article-title>Gene expression profiling of bronchoalveolar lavage cells preceding a clinical diagnosis of chronic lung allograft dysfunction</article-title><source>PLoS One</source><volume>12</volume><year>2017</year><comment>e0169894</comment></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A.E.</given-names></name><name><surname>Bracamonte-Baran</surname><given-names>W.</given-names></name><name><surname>Burlingham</surname><given-names>W.J.</given-names></name></person-group><article-title>Donor-derived exosomes: the trick behind the semidirect pathway of allorecognition</article-title><source>Curr Opin Organ Transplant</source><volume>22</volume><year>2017</year><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">27898464</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Rojas-Canales</surname><given-names>D.M.</given-names></name><name><surname>Divito</surname><given-names>S.J.</given-names></name><name><surname>Shufesky</surname><given-names>W.J.</given-names></name><name><surname>Stolz</surname><given-names>D.B.</given-names></name><name><surname>Erdos</surname><given-names>G.</given-names></name></person-group><article-title>Donor dendritic cell-derived exosomes promote allograft-targeting immune response</article-title><source>J Clin Invest</source><volume>126</volume><year>2016</year><fpage>2805</fpage><lpage>2820</lpage><pub-id pub-id-type="pmid">27348586</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Gunasekaran</surname><given-names>M.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Hachem</surname><given-names>R.</given-names></name><name><surname>Bremner</surname><given-names>R.</given-names></name><name><surname>Smith</surname><given-names>M.A.</given-names></name><name><surname>Mohanakumar</surname><given-names>T.</given-names></name></person-group><article-title>Circulating exosomes with distinct properties during chronic lung allograft rejection</article-title><source>J Immunol</source><volume>200</volume><year>2018</year><fpage>2535</fpage><lpage>2541</lpage><pub-id pub-id-type="pmid">29491008</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Perincheri</surname><given-names>S.</given-names></name><name><surname>Gunasekaran</surname><given-names>M.</given-names></name><name><surname>Mohanakumar</surname><given-names>T.</given-names></name></person-group><article-title>Exosomes expressing the self-antigens myosin and vimentin play an important role in syngeneic cardiac transplant rejection induced by antibodies to cardiac myosin</article-title><source>Am J Transplant</source><volume>18</volume><year>2018</year><fpage>1626</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">29316217</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Dieude</surname><given-names>M.</given-names></name><name><surname>Bell</surname><given-names>C.</given-names></name><name><surname>Turgeon</surname><given-names>J.</given-names></name><name><surname>Beillevaire</surname><given-names>D.</given-names></name><name><surname>Pomerleau</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name></person-group><article-title>The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerated rejection</article-title><source>Sci Transl Med</source><volume>7</volume><year>2015</year><comment>318ra200</comment></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Tower</surname><given-names>C.M.</given-names></name><name><surname>Reyes</surname><given-names>M.</given-names></name><name><surname>Nelson</surname><given-names>K.</given-names></name><name><surname>Leca</surname><given-names>N.</given-names></name><name><surname>Kieran</surname><given-names>N.</given-names></name><name><surname>Muczynski</surname><given-names>K.</given-names></name></person-group><article-title>Plasma C4d+ endothelial microvesicles increase in acute antibody-mediated rejection</article-title><source>Transplantation</source><volume>101</volume><year>2017</year><fpage>2235</fpage><lpage>2243</lpage><pub-id pub-id-type="pmid">27846156</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary Data</title><p id="p0175"><supplementary-material content-type="local-data" id="mmc1"><caption><title>Video 1</title><p>Exosomes in lung trasplant outcomes: Circulatory exosomes with lung-associated antigens are present in primary graft dysfunction, before development of donor-specific antibodies, acute rejection, and chronic rejection. Therefore, circulatory exosomes with lung-associated antigens are a novel mechanism of inducing immune responses leading to rejection of graft after lung transplantation. Video available at: <ext-link ext-link-type="uri" xlink:href="https://www.jtcvs.org/article/S0022-5223(19)30343-5/fulltext" id="interref0010a">https://www.jtcvs.org/article/S0022-5223(19)30343-5/fulltext</ext-link>.</p></caption><media xlink:href="mmc1.flv"></media></supplementary-material></p></sec><ack id="ack0010"><p>We thank Clare Sonntag and Billie Glasscock for their assistance in submitting this paper.</p></ack><fn-group><fn id="d32e1824"><p id="ntpara0010">This work was supported by grants from the <funding-source id="gs1">National Institutes of Health</funding-source>R21AI123034, HL092514, and HL056643 (to T.M.).</p></fn></fn-group></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000941 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000941 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6625531
|texte= A novel mechanism for immune regulation after human lung transplantation
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31288367" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |